At the news
? BULLISHIMPACT 7/10 8-K filed Jul 7, 2026 at 12:45 ET
Vera Therapeutics announced FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. This is a transformative regulatory milestone that unlocks a commercial market for the company's lead drug candidate.
- FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) on July 7, 2026.
- Indication: reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.
- No financial terms, pricing, or revenue guidance were disclosed in the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access